CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 105 participants.
Also called NCT05356403
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 105 participants
- Sponsor
- Registry
-
NCT05356403
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Germany, Hungary, Italy, Mexico, Poland, Romania, South Korea, Spain
- Registry status
- Terminated
Technical summary
Registry record NCT05356403. Randomized; double masking; primary purpose treatment. Start 2022-08-26 (actual); primary completion 2024-02-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- Condition
- Chronic Kidney Diseases
- Condition
- Pruritus
- Intervention (Drug)
- Difelikefalin 1 mg Oral Tablet
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- Cara Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct05356403- Content hash
283dd4487ea096f3742e7a7ef5553aeefab0897f2f15ffa1c42ccac27414f82d